Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

被引:0
|
作者
Cashin, Peter Harald [1 ]
Asplund, Dan [2 ,6 ]
Lindskog, Elinor Bexe [2 ]
Ghanipour, Lana [1 ]
Syk, Ingvar [3 ]
Graf, Wilhelm [1 ]
Nilsson, Per J. [4 ,5 ]
Palmer, Gabriella Jansson [4 ,5 ]
机构
[1] Uppsala Univ Hosp, Uppsala, Sweden
[2] Sahlgrens Univ Hosp, Dept Surg, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Skanes Univ Hosp, Malmo, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Surg, Gothenburg, Sweden
关键词
Colorectal cancer; Peritoneal metastases; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Relapse treatment; Systemic chemotherapy; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MULTICENTER; PROGNOSIS; CANCERS;
D O I
10.1016/j.sopen.2024.05.018
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated. Objectives: To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease. Methods: Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated. Results: Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30-58) in the interventional group and 19 months (95%CI: 15-24) in the palliative group (HR 0.35 95%CI: 0.20-0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38-45). Conclusion: After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [21] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Summary of Key Clinical Trials
    Turner, Kevin M.
    Morris, Mackenzie C.
    Sohal, Davendra
    Sussman, Jeffrey J.
    Wilson, Gregory C.
    Ahmad, Syed A.
    Patel, Sameer H.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (12)
  • [22] Peritoneal metastatic colorectal Cancer: cytoreductive Surgery and hyperthermic intraperitoneal Chemotherapy
    Koenigsrainer, I.
    Beckert, S.
    Bruecher, B.
    Zieker, D.
    Koenigsrainer, A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (36) : 1811 - 1814
  • [23] Management of peritoneal surface metastases from colorectal cancer: Cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, pressurized intraperitoneal chemotherapy, and beyond
    Mangieri, Christopher W.
    Levine, Edward A.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: from novelty to routine in selected cases
    B. J. Moran
    Techniques in Coloproctology, 2017, 21 : 767 - 769
  • [25] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: from novelty to routine in selected cases
    Moran, B. J.
    TECHNIQUES IN COLOPROCTOLOGY, 2017, 21 (09) : 767 - 769
  • [26] Outcomes of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in 66 patients with colorectal peritoneal metastases
    Fallis, S. A.
    Ansari, N.
    Mohamed, F.
    Cecil, T. D.
    Moran, B. J.
    BRITISH JOURNAL OF SURGERY, 2015, 102 : 25 - 25
  • [27] Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Wijntje J. van Eden
    Fortuné M. K. Elekonawo
    Bas J. Starremans
    Niels F. M. Kok
    André J. A. Bremers
    Johannes H. W. de Wilt
    Arend G. J. Aalbers
    Annals of Surgical Oncology, 2018, 25 : 1992 - 2001
  • [28] Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    van Eden, Wijntje J.
    Elekonawo, Fortune M. K.
    Starremans, Bas J.
    Kok, Niels F. M.
    Bremers, Andre J. A.
    de Wilt, Johannes H. W.
    Aalbers, Arend G. J.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (07) : 1992 - 2001
  • [29] Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    van Eden, W. J.
    Elekonawo, F. M.
    Starremans, B. J.
    Kok, N.
    Bremers, A. J.
    de Wilt, H.
    Aalbers, A.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S35 - S35
  • [30] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Colorectal Peritoneal Metastasis
    Seo, C.
    Wong, J.
    Sin, E.
    Tan, G.
    Chia, C.
    Teo, M.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S81 - S81